Cardiff Oncology, Nerviano settle onvansertib rights lawsuit, seek dismissal with prejudice

• Cardiff Oncology reached a settlement with Nerviano Medical Sciences tied to litigation over global rights to onvansertib.
• Both sides agreed to a full mutual release of claims in a U.S. District Court case in Southern District of California.
• The parties plan to seek dismissal of all claims with prejudice under an amended 2017 exclusive license agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140830PRIMZONEFULLFEED9826162) on September 14, 2026, and is solely responsible for the information contained therein.